UK markets close in 1 hour 53 minutes
  • FTSE 100

    7,087.08
    +70.45 (+1.00%)
     
  • FTSE 250

    23,023.56
    +17.11 (+0.07%)
     
  • AIM

    1,247.53
    +5.76 (+0.46%)
     
  • GBP/EUR

    1.1756
    +0.0019 (+0.16%)
     
  • GBP/USD

    1.3965
    +0.0057 (+0.41%)
     
  • BTC-GBP

    28,597.59
    +136.07 (+0.48%)
     
  • CMC Crypto 200

    938.10
    +7.74 (+0.83%)
     
  • S&P 500

    4,419.18
    +18.54 (+0.42%)
     
  • DOW

    35,119.19
    +188.26 (+0.54%)
     
  • CRUDE OIL

    72.90
    +0.51 (+0.70%)
     
  • GOLD FUTURES

    1,829.40
    +24.80 (+1.37%)
     
  • NIKKEI 225

    27,782.42
    +200.76 (+0.73%)
     
  • HANG SENG

    26,315.32
    +841.44 (+3.30%)
     
  • DAX

    15,626.76
    +56.40 (+0.36%)
     
  • CAC 40

    6,650.52
    +41.21 (+0.62%)
     

Government will set out plans for Covid-19 booster campaign – Matt Hancock

·5-min read

Data is due in the coming weeks on whether mixing Covid-19 vaccines could offer the template for an autumn booster vaccine campaign, the Health Secretary has said.

Matt Hancock said that while second doses of the current vaccines offered very strong protection, “there is more protection still that we think that you can get from a booster jab”.

He said there was a need to “get the logistics right” for any future vaccine campaign after GPs and NHS leaders expressed concern about how it would be staffed.

Seven vaccines are currently being tested in the Cov-Boost trial to see which could be used in any forthcoming autumn vaccination programme.

Experts believe that all seven vaccines will boost immunity, and lab studies are checking their response to variants circulating in the UK, including those first identified in India, Kent and South Africa.

Watch: Matt Hancock looking at "extra freedoms" for double-jabbed

The £19.3 million UK clinical trial is testing the Pfizer jab alongside those from AstraZeneca, Moderna, Novavax, Janssen from Johnson & Johnson, Valneva and CureVac.

The study will examine key questions such as whether people who have had two doses of AstraZeneca may get more benefit from a third dose of Pfizer.

“When we know the results of that (trial), then we will set out the full plans for the booster programme over the autumn,” Mr Hancock told BBC Breakfast on Monday.

“We’ve got to make sure we get the logistics right; for instance, GPs have been so heavily involved in this vaccination effort, but GPs have also got to do their day job, so that’s something we’re working hard on now and, in the next few weeks, when we get the clinical data through on what’s the most effective combinations to have… then we’ll set out all the details of the booster programme for the autumn.”

Professor Saul Faust, lead investigator of the booster vaccine trial, said his team would be able to provide data to the Joint Committee on Vaccination and Immunisation (JCVI) by the “end of August”.

The University of Southampton academic told BBC Radio 4’s World At One programme: “I’m not the right person to say definitely, but it sounded very much like the Secretary of State (Matt Hancock) is expecting to announce a booster programme.

“From the trial point of view, we’ve got very tight timelines. The results of the trial, both in terms of the side effects and the blood test data which shows immunology and how the vaccines are working against all the current circulating variants, those data will be available to JCVI by the end of August.

“That is incredibly quick in terms of the fact we are still recruiting – the recruitment for this trial, giving people their third dose, is happening right now in June.”

Last week, Professor Sir Andrew Pollard, head of the Oxford Vaccine Group, told MPs “we have absolutely no evidence that there is a need for a third dose” at the moment.

He said the UK was seeing “very high levels of protection against hospitalisation with two doses” using current vaccines and it was too early to say when protection would wane.

Professor Martin Marshall, chair of Royal College of GPs, told BBC Radio 4’s Today programme on Monday that any booster programme needed to be properly resourced.

He said: “I do believe that general practice has a very important role to play because we were part of the successes of the current programme because general practice knows how to do it.

“But it needs to be adequately resourced to allow us to do it well.

“We can’t have GPs and practice nurses and pharmacists diverted away from normal business, because we can’t afford to let our patients down on all the many other things that we do in general practice.”

Daily confirmed cases of Covid-19 in the UK
(PA Graphics)

He suggested booster campaigns might be conducted by non-clinical, trained staff to free up time for doctors and nurses.

He added that general practices administer large flu campaigns in the winter and asked whether it would be possible to give a Covid-19 jab at the same time as “clearly that would be a very efficient process”.

Chris Hopson, chief executive of NHS Providers, said the health service needs time to plan for potential Covid-19 vaccine booster campaigns to make them “business as usual” instead of “emergency response”.

He told Times Radio: “Flu jabs start in September, so if we’re going to do one jab in one arm, one jab in the other, we really do need to know quite quickly.”

He said Covid-19 vaccines were “probably” going to be needed on “an annual basis for, I don’t know, at least five, six, seven, eight, nine, 10 years.”

Covid-19 vaccine doses in the UK
(PA Graphics)

Meanwhile, Professor Anthony Harnden, deputy chairman of the JCVI, said he thought flu could be a “bigger problem” than Covid-19 this winter.

He added: “I will emphasise that actually flu could be potentially a bigger problem this winter than Covid-19.

“We’ve had a very, very low prevalence of flu for the last few years, particularly virtually nil during lockdown, and we do know that when flu has been circulating in very low numbers immunity drops in the population, and it comes back to bite us. So, flu can be really, really important this winter.”

Elsewhere, Calum Semple, a member of the Scientific Advisory Group for Emergencies (Sage) and professor of child health and outbreak medicine at the University of Liverpool, told Sky News “it’s a really close call” on whether children should be vaccinated, given their low risk of serious illness from Covid-19.

He added: “The knowledge around safety in children is growing, but I would say it’s not as robust as it needs to be if there was to be blanket vaccination of children who themselves are not at risk of very severe disease.

“That’s the crux of the matter. If you are going to vaccinate children to protect society, that is a fair decision that can be made, but you want to do that with full knowledge of the safety data.”

Watch: What UK government COVID-19 support is available?

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting